STOCK TITAN

Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

GLSI NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
103 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+21.7% close of January 7, 2026
1-year change
+65.4% closing prices, November 14, 2025 to November 16, 2026
1-month change
-5.4% closing prices, October 16, 2026 to November 16, 2026

Company Description

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company in the pharmaceutical preparation manufacturing industry. The company is focused on developing GLSI-100, an immunotherapy intended to prevent breast cancer recurrences, and on conducting its Phase III clinical trial known as FLAMINGO-01 (NCT05232916). According to company disclosures and press releases, GLSI-100 combines GP2, a 9 amino acid transmembrane peptide of the HER2/neu protein, with GM-CSF. HER2/neu is a cell surface receptor protein expressed in a variety of common cancers, including a large proportion of breast cancers.

Greenwich LifeSciences states that FLAMINGO-01 is designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab-based treatment. The trial is led by Baylor College of Medicine and includes clinical sites in the United States and Europe from university-based hospitals and academic and cooperative networks, with plans disclosed by the company to open up to 150 sites globally.

GLSI-100 and the FLAMINGO-01 Trial Design

In company communications, GLSI-100 is described as GP2 plus GM-CSF. GP2 is characterized as a 9 amino acid transmembrane peptide of the HER2/neu protein, which is expressed in many cancers and in an estimated 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination with GM-CSF is intended to stimulate an immune response against HER2-expressing cancer cells. The FLAMINGO-01 Phase III trial includes double-blinded randomized arms and an open label arm:

  • Approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo in double-blinded arms.
  • Up to 250 patients of other HLA types (non-HLA-A*02) are planned to be treated with GLSI-100 in a third, open label arm.
  • The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, with 28 events required and an interim analysis for superiority and futility planned when at least 14 events have occurred.

The company reports that FLAMINGO-01 has screened more than 1,000 patients across approximately 40 U.S. sites and 100 European sites, with a screening rate of about 600 patients per year. Greenwich LifeSciences has also disclosed plans and regulatory approvals to expand the trial into multiple European countries, including Spain, France, Germany, Italy, Poland, Romania, Ireland, Portugal, Belgium, and Austria, in addition to the U.S.

Clinical Data and Development History

Greenwich LifeSciences highlights prior clinical data from a Phase IIb trial of GLSI-100 in HLA-A*02 breast cancer patients. In this prospective, randomized, single-blinded, placebo-controlled, multi-center study led by MD Anderson Cancer Center, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100 and 50 placebo patients received GM-CSF alone. The company reports that, after 5 years of follow-up, there was an 80% or greater reduction in metastatic breast cancer recurrence rate in the GLSI-100–treated HER2/neu 3+ patients who were treated, followed, and remained disease free over the first 6 months. The primary immunization series (PIS), consisting of the first 6 GLSI-100 injections over the first 6 months, was associated with a peak immune response at 6 months, and the company describes the safety profile as well tolerated with no reported serious adverse events attributable to treatment in the Phase IIb and earlier Phase I studies.

In FLAMINGO-01, Greenwich LifeSciences reports that the 250-patient non-HLA-A*02 open label arm has been fully enrolled, with all patients receiving GLSI-100. Preliminary analyses disclosed by the company indicate an approximately 80% reduction in recurrence rate in this arm after completion of the PIS, based on comparisons to expected historical recurrence rates and internal comparisons of recurrence rates before and after the PIS. The company emphasizes that these results are preliminary, based on data that are not yet complete or fully reviewed, and that final outcomes may differ.

Regulatory Status and Fast Track Designation

The company has announced that the U.S. Food and Drug Administration granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population. The designation, as quoted by the company, applies to GLSI-100 for the treatment of patients with HLA-A*02 genotype and HER2-positive breast cancer who have completed standard of care HER2/neu targeted therapy, with the goal of improving invasive breast cancer-free survival. Greenwich LifeSciences notes that Fast Track designation may enable more frequent communication with the FDA, potential use of rolling review for a future Biologic License Application, and possible eligibility for other expedited review mechanisms if criteria are met.

Corporate Governance and Exchange Listing

Greenwich LifeSciences is incorporated as Greenwich LifeSciences, Inc. and its common stock trades on Nasdaq under the symbol GLSI. The company holds annual meetings of stockholders, as described in its definitive proxy statements and related Form 8-K filings. For example, an 8-K dated December 18, 2025 reports the results of the 2025 Annual Meeting of Stockholders, including the election of directors and ratification of the appointment of MaloneBailey LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2025.

In a separate Form 8-K dated July 24, 2025, the company disclosed that its audit committee approved the dismissal of RBSM LLP as its independent registered public accounting firm and the engagement of MaloneBailey LLP to audit the company’s consolidated financial statements for the year ended December 31, 2025. The filing notes that RBSM’s prior reports did not contain adverse opinions or disclaimers of opinion and describes identified material weaknesses in internal control over financial reporting, as discussed in the company’s periodic reports.

Breast Cancer and HER2/neu Context

In its public communications, Greenwich LifeSciences cites widely used breast cancer statistics to frame the potential clinical setting for GLSI-100. The company notes that one in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. It also states that HER2 (human epidermal growth factor receptor 2) is expressed in about 75% of breast cancers at varying levels (low, intermediate, and high). These figures are presented by the company as context for the potential population in which GLSI-100 and the FLAMINGO-01 trial are being studied.

Business Focus

Based on the available information, Greenwich LifeSciences’ business model centers on the clinical development and potential future commercialization of GLSI-100 as an immunotherapy product candidate. The company’s disclosures focus on clinical trial execution, regulatory strategy, and intellectual property around the use of GLSI-100 in specific patient populations, including HLA-A*02 and non-HLA-A*02 HER2-positive breast cancer patients. The company also discusses financing approaches, such as at-the-market (ATM) offerings, and partnering strategies in its press releases, but detailed revenue-generating activities beyond development are not described in the provided materials.

Key Points for Investors and Observers

  • GLSI is a clinical-stage biopharmaceutical company; its main asset, GLSI-100, is in Phase III development and is not described in the sources as an approved therapy.
  • The company’s primary clinical program, FLAMINGO-01, targets HER2-positive breast cancer patients who have completed trastuzumab-based therapy and had residual disease or high-risk pathologic complete response at surgery.
  • GLSI-100 has received FDA Fast Track designation in the HLA-A*02 genotype population, which may affect the regulatory pathway.
  • Preliminary open label data in non-HLA-A*02 patients and prior Phase IIb results in HLA-A*02 patients, as reported by the company, suggest substantial reductions in recurrence rates, but the company explicitly cautions that preliminary Phase III data are not predictive of final outcomes.
  • The company remains listed on Nasdaq and continues to file proxy materials, 8-Ks, and other reports with the SEC, reflecting ongoing corporate governance and reporting obligations.

All information above is drawn from company press releases and SEC filings provided in the source data and reflects how Greenwich LifeSciences describes its own operations, clinical programs, and regulatory status.

Stock Performance

$13.95
+1.38%
+0.19
After hoursChange vs the $13.76 closeLast updated: November 16, 2026 at 18:55
+65.4%
Performance 1 year
$204.8M

Greenwich LifeSciences (GLSI) closed at $13.76 on November 16, 2026. Over the past 12 months, the price has gained 65.4%.

See what a $1,000 investment in GLSI would be worth today

Average down calculator for GLSI

GLSI Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Greenwich LifeSciences reported operating income of -$19.4M in FY2025, and net income was -$19.4M. Diluted earnings per share stood at -$1.43. The company generated -$9.9M in operating cash flow. The current ratio was 1.06, measuring current assets divided by current liabilities.

-$19.4M
Net Income (FY2025)
-$9.9M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

DEC
08
December 8, 2026 - December 11, 2026 Clinical

SABCS 2026 Conference

San Antonio Breast Cancer Symposium running Dec 8–11, 2026 where GLSI will present trial data and post materials on its website.
DEC
09
December 9, 2026 Clinical

Poster Presentations

Two FLAMINGO-01 posters scheduled for Dec 9, 2026 in late-breaking/ongoing trials sessions; posters to be posted on GLSI website.
JAN
31
January 31, 2027 Financial

Lock-up Expiration

Board-extended 100% lock-up on directors, officers and pre-IPO investors ends; leak-out/10b5-1 sales expected thereafter.

Greenwich LifeSciences has 3 upcoming scheduled events. The next event, "SABCS 2026 Conference", is scheduled for December 8, 2026 (in 21 days). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the GLSI stock price.

Short Interest History

Last 12 Months

Short interest in Greenwich LifeSciences (GLSI) currently stands at 1.6 million shares, up 1.7% from the previous reporting period, representing 20.7% of the float.

Days to Cover History

Last 12 Months

Days to cover for Greenwich LifeSciences (GLSI) currently stands at 12.5 days, up 16.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 54.2%. Across the settlements charted above, it has ranged from 1.3 to 27.3 days.

GLSI Company Profile & Sector Positioning

Greenwich LifeSciences (GLSI) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing GLSI often look at related companies in the same sector, including ProKidney Corp. (PROK), Immuneering Corporation (IMRX), Inhibikase Therapeutics, Inc. (IKT), Arcturus Therapeutics Holdings Inc. (ARCT), and Lexeo Therapeutics, Inc. (LXEO). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate GLSI's relative position within its industry.

Frequently Asked Questions

The current stock price of Greenwich LifeSciences (GLSI) is $13.95 in after-hours trading as of November 16, 2026.

The market cap of Greenwich LifeSciences (GLSI) is approximately $204.8M. Learn more about what market capitalization means .

The FY2025 net income of Greenwich LifeSciences (GLSI) is -$19.4M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Greenwich LifeSciences (GLSI) is -$1.43 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Greenwich LifeSciences (GLSI) is -$9.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Greenwich LifeSciences (GLSI), current assets divided by current liabilities, was 1.06 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Greenwich LifeSciences (GLSI) is -$19.4M for FY2025, its most recent completed fiscal year. Learn about operating income.

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing GLSI-100, an immunotherapy intended to prevent breast cancer recurrences. Its main clinical program is the Phase III FLAMINGO-01 trial in HER2-positive breast cancer patients who have completed trastuzumab-based therapy and had residual disease or high-risk pathologic complete response at surgery.

According to company disclosures, GLSI-100 is a combination of GP2, a 9 amino acid transmembrane peptide of the HER2/neu protein, and GM-CSF. It is being developed as an immunotherapy to reduce breast cancer recurrences in HER2-positive patients and is the investigational product in the FLAMINGO-01 Phase III trial.

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial sponsored by Greenwich LifeSciences to evaluate the safety and efficacy of GLSI-100 in HER2-positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed neoadjuvant and postoperative adjuvant trastuzumab-based treatment. The trial includes randomized double-blinded arms in HLA-A*02 patients and an open label arm in non-HLA-A*02 patients.

The company cites a prospective, randomized, single-blinded, placebo-controlled, multi-center Phase IIb trial in HLA-A*02 breast cancer patients, where 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100 and 50 received GM-CSF alone. After 5 years of follow-up, Greenwich LifeSciences reports an 80% or greater reduction in metastatic breast cancer recurrence rate in GLSI-100–treated HER2/neu 3+ patients who remained disease free over the first 6 months, with a peak immune response at 6 months and a well-tolerated safety profile.

Yes. Greenwich LifeSciences has announced that the U.S. Food and Drug Administration granted Fast Track designation for GLSI-100 in patients with HLA-A*02 genotype and HER2-positive breast cancer who have completed standard of care HER2/neu targeted therapy, with the goal of improving invasive breast cancer-free survival.

In FLAMINGO-01, HLA-A*02 refers to patients who carry the HLA-A*02 allele. Approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo in double-blinded arms. Non-HLA-A*02 patients do not have the HLA-A*02 allele from either parent and represent a separate population; up to 250 of these patients are planned to be treated with GLSI-100 in an open label arm, which the company reports has been fully enrolled.

The company has reported preliminary analyses from the fully enrolled 250-patient non-HLA-A*02 open label arm, indicating an approximately 80% reduction in recurrence rate after completion of the primary immunization series, based on comparisons to historical recurrence rates and internal comparisons before and after the primary immunization series. Greenwich LifeSciences emphasizes that these data are preliminary, based on incomplete and not fully reviewed information, and that final study results may differ.

In the provided materials, GLSI-100 is consistently described as an investigational immunotherapy in clinical development. It is being studied in the Phase III FLAMINGO-01 trial and has received Fast Track designation, but the sources do not state that it has been approved as a breast cancer treatment.

Greenwich LifeSciences, Inc. trades on Nasdaq under the ticker symbol GLSI, as stated in multiple company press releases and SEC filings.

Corporate governance information, such as the election of directors and the appointment of the independent registered public accounting firm, is disclosed in the company’s definitive proxy statements (DEF 14A) and related Form 8-K filings. For example, an 8-K dated December 18, 2025 reports the results of the 2025 Annual Meeting of Stockholders, and an 8-K dated July 24, 2025 describes the change in the company’s independent registered public accounting firm.